Morgan Stanley Maintains Equal-Weight on Nevro, Lowers Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Cecilia Furlong maintains an Equal-Weight rating on Nevro (NYSE:NVRO) and lowers the price target from $23 to $18.
November 02, 2023 | 6:47 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on Nevro and lowered the price target from $23 to $18.
The lowering of the price target by Morgan Stanley from $23 to $18 indicates a bearish outlook for Nevro in the short term. This could potentially lead to a decrease in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100